• Jordan Jones, Hong Nguyen, Katharine Drummond, and Andrew Morokoff.
• Department of Surgery, University of Melbourne, Melbourne, Australia.
• Neurosurgery. 2021 Feb 16; 88 (3): E221-E230.

AbstractAccurate circulating biomarkers have potential clinical applications in population screening, tumor subclassification, monitoring tumor status, and the delivery of individualized treatments resulting from tumor genotyping. Recently, significant progress has been made within this field in several cancer types, but despite the many potential benefits, currently there is no validated circulating biomarker test for patients with glioma. A number of circulating factors have been examined, including circulating tumor cells, cell-free DNA, microRNA, exosomes, and proteins from both peripheral blood and cerebrospinal fluid with variable results. In the following article, we provide a narrative review of the current evidence pertaining to circulating biomarkers in patients with glioma, including discussion of the advantages and challenges encountered with the current methods used for discovery. Additionally, the potential clinical applications are described with reference to the literature.© Congress of Neurological Surgeons 2021.

25 keywords...

hide…